AstraZeneca mines another $6B ADC from Daiichi Sankyo, with blockbuster ambitions to ‘redefine treatment standards’
Pascal Soriot isn’t letting the all-consuming R&D and manufacturing work on a Covid-19 vaccine slow down his hunt for AstraZeneca’s next blockbuster cancer drugs.
The latest deal with Daiichi Sankyo consists of $1 billion in upfront cash payment spread over 2 years: $350 million upon completion, and $325 million each at the 12-month and 24-month mark. Regulatory milestones add up to another $1 billion while sales-related fees tot up to $4 billion.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 86,800+ biopharma pros reading Endpoints daily — and it's free.